Download Agenda

Accessible on Mobile devices at http://mobile.cednc.org/

DAY ONE: Wednesday, February 15, 2012

9:30 am- 6:30 pm

Registration Open to All Conference Attendees

10:00 am –  4:30 pm    

Partnering Meetings

Emerging life science companies, venture capitalists & other investors and large pharma & medtech

10:00 am – 12:45 pm    

Entrepreneur Workshop:  Bulding Value Through Corporate Partnerships (By Invitation Only)

• Gautam Aggarwal, Senior Practice Executive, Campbell Alliance
• Kenneth Eheman, Partner, Wyrick Robbins
• Kinney Horn, Associate Director in Business Development, Genentech
• Ajay Rai, Director, Business Development and M&A, Biogen Idec
  
• Steven E. Hall, Ph.D., Venture Partner, Lilly Ventures
• Robert J. Schotzinger, M.D., Ph.D., President and CEO, Viamet Pharmaceuticals

11:30 pm – 12:45 pm     

Joint Board Lunch: CED, NC Biotechnology Center, NC Biosciences Organization (By Invitation Only)

Conference Opens

1:00 pm – 2:00 pm   

Opening Remarks and Featured Speaker

• Joan Siefert Rose, President, CED
• Victor J. Dzau, M.D., President and Chief Executive Officer, Duke University Health System and Chancellor for Health Affairs, Duke University
• The Honorable James B. Hunt Jr., Govenor of North Carolina (1977-1985, 1993-2001) and Partner, Womble Carlyle Sandridge & Rice LLP
  
• Christopher A. Viehbacher, Chief Executive Officer, Sanofi

2:00 pm – 2:30 pm  

Health Science Transformation Trends & Impacts: Beyond the Hype of Health Reform

• R.T. (Terry) Hisey, Vice Chairman and U.S. Life Sciences Leader, Deloitte LLP
  

2:30 pm – 3:00 pm    

Break

3:00 pm – 4:00 pm  

Funding and strategic innovation: Perspectives from VCs, Industry and Public Market Investors

• Kris H. Jenner M.D.,D.Phil., Head of Life Science Investments, T. Rowe Price Associates, Inc. (Moderator)
• James Geraghty, Senior Vice President, North American Strategy and Business Development, Genzyme, a Sanofi Company
  
• Chris Hite, Head of Global Healthcare Investment Banking, Citigroup 
  
• Mark Levin D.Phil., Partner, Third Rock Ventures 
• Bill Slattery, Partner, Deerfield Management Company L.P.

4:00 pm – 4:30 pm  

 Break

4:30 pm – 6:00 pm    

Emerging Company Showcase

Biopharma

• Aerial BioPharma LLC
  
• Chimerix, Inc.
  
• CoLucid Pharmaceuticals, Inc.
  
• Heat Biologics
• Liquidia Technologies
• SCYNEXIS, Inc.
  
• Vascular Pharmaceuticals, Inc.
  
• Viamet Pharmaceuticals, Inc.
  

Medtech

• Advanced Animal Diagnostics, Inc.
  
• Advanced Liquid Logic, Inc.
  
• Clearside Biomedical, Inc.
  
• Humacyte
• Metabolon, Inc.
  
• nContact, Inc.
  
• TearScience
• TransEnterix, Inc.
  

6:00 pm – 7:30 pm    

Gala Reception

7:30 pm – 9:30 pm    

Investor Dinner (by invitation only)

DAY TWO: Thursday, February 16, 2012

7:30 am - 12:30 pm

Registration is Open to All Conference Attendees

7:30 am – 8:30 am

CEO Breakfast (invitation only)

• William A Hawkins, III, President & Chief Executive Officer, Immucor, Inc. (Retired Chairman and Chief Executive Officer, Medtronic, Inc.)

---

 7:30 am - 8:30 am 

Continental Breakfast

8:00 am - 12:30 pm 

Partnering Meetings

8:30 am – 9:30 am

Opening Remarks

• Alex Gorsky, Vice Chairman, Executive Committee, Office of the Chairman,  J&J
• Mehmood Khan, M.D., Chief Scientific Officer and Chief Executive Officer, Global Nutrition Group, PepsiCo, Inc.
  

9:30 am – 10:00 am    

Break

10:00 am – 12:30 pm    

Venture Day Hosted by Sanofi (VC Investors Only, By Invitation)

10:00 am – 11:00 am    

CEO Panel: How To Survive in 2012 and beyond

• Vipin K. Garg, Ph.D., President and Chief Executive Officer, Tranzyme Pharma (Moderator)
• Neal Fowler, Chief Executive Officer, Liquidia Technologies
  
• David Levison,  President and Chief Executive Officer, CardioDx, Inc.
  
• Mark A. Sirgo, Pharm.D., President and Chief Executive Officer, BioDelivery Sciences International, Inc.
• Tim Willis, President, President and Chief Executive Officer,  TearScience

11:00 am – 11:30 am

Break

11:30 am – 12:30 pm

Reimbursement Panel

• Colin Roskey, Partner, Alston & Bird LLP (Moderator)
• Jack Bailey, Senior Vice President, Policy, Payers and Vaccines, GlaxoSmithKline
• Eric Faulkner, Director, Global Market Access, Quintiles
• Amy L. Grogg, Pharm.D., President, Xcenda
  
• Ann-Marie Lynch, Executive Vice President Payment and Health Care Delivery, The Advanced Medical Technology Association (AdvaMed)

12:30 pm – 2:30 pm

Closing Lunch

• Special Presentation by Regional Finalists in the Siemens Competition in Math, Science and Technology
  •  Aakash Indurkhya and Peter Fan, North Carolina School of Science and Mathematics
• Presentation of the Life Science Leadership Award
  • Introductory remarks by Kenneth R. Tindell, Ph.D., Senior Vice President, Science and Business Development, North Carolina Biotechnology Center
  • Samuel M. Taylor
• Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium: The Takeda Oncology Company

2:30 pm – 5:00 pm

Grants Workshop (In Partnership with SBTDC)

SBIR Overview

• John Ujvari, SBIR Program Specialist, NC SBTDC

NIH Funding overview

• Daniel Shaughnessy, Ph.D., Susceptibility & Population Health Branch, Division of Extramural Research & Training, National Institute of Environmental Health Sciences

DoD Funding overview

• Nicole R. Fox, SBIR/STTR Program Coordinator, US Army Research Office

Break

Grants Review

• Dale Christensen, Ph.D., President & Chief Scientific Officer, Oncotide Pharmaceuticals, Inc.
  

Awardees’ Panel

• Dale Christensen, Ph.D., President & Chief Scientific Officer, Oncotide Pharmaceuticals
• Mark Clemens, Ph.D., VP & Senior Scientific Officer, HepatoSys Inc.
• Caroline Green, Integration, Quality and Regulatory Manager, InnerOptic Technology, Inc.

5:00 pm

Conference close

Christopher A. Viehbacher
CEO
Sanofi

Christopher A. Viehbacher, born March 26, 1960, holds German and Canadian nationalities. He is a graduate of the Queens University (Ontario - Canada) and a certified public accountant.

After beginning his career at PriceWaterhouseCoopers, between 1988-2008 he acquired broad international experience in Europe, in the United States and in Canada with the GlaxoSmithKline (GSK) company. In his last position, Christopher A. Viehbacher was President, Pharmaceutical Operations North America, a member of the board and Co-Chairman of the Portfolio Management Board. As from December 1, 2008, Christopher A. Viehbacher is a sanofi-aventis board member, CEO and a member of the Strategy Committee. He is also President and CEO of Genzyme since April 2011.

Christopher A. Viehbacher is Chairman of PhRMA in the United States since December 2010 and was elected Chair of the CEO Roundtable on Cancer in February 2011. Christopher A. Viehbacher is married with three children. He speaks French, English and German: he lived in France for nine years when he was General Manager of GSK France. He was made a knight of the French Legion of Honor in 2003.

Alex Gorsky
Vice Chairman of Executive Committee
Johnson & Johnson

Alex Gorsky is Vice Chairman of Johnson & Johnson’s Executive Committee, the Company’s senior-most leadership team.  He assumed this role in January 2011.  As Vice Chairman, Alex is responsible for Johnson & Johnson’s Medical Devices & Diagnostics Group, the largest business of its kind in the world; Johnson & Johnson Supply Chain, which includes a global network of 140 manufacturing facilities; the Company’s Government Affairs & Policy Group; and the Johnson & Johnson Development Corporation, the Company’s venture capital subsidiary.

Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988.  Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management.  In 2001, Alex was appointed President of Janssen, and in 2003, he was named Company Group Chairman of Johnson & Johnson’s pharmaceuticals business in Europe, the Middle East and Africa.  

Alex left Johnson & Johnson in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company’s pharmaceuticals business in North America.

Alex returned to Johnson & Johnson in 2008 as Company Group Chairman for Ethicon.  In early 2009, he was appointed Worldwide Chairman of the Surgical Care Group and also was appointed to the Johnson & Johnson Executive Committee.  In September 2009, he was appointed Worldwide Chairman of the Medical Devices & Diagnostics Group.

Alex represents Johnson & Johnson on the board of AdvaMed, the U.S. trade association for the medical device and diagnostics industry.   A longtime advocate of diversity and inclusion, Alex was named the 2009 Mentor of the Year by the Healthcare Businesswomen’s Association, an organization he has been involved with for many years.   He is the Executive Sponsor of two Johnson & Johnson affinity groups, the Women’s Leadership Initiative and the Veteran’s Leadership Council

Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain.  Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.

He and his wife, Pat, have a son, Nicholas.

Jack Bailey
Senior Vice President
GlaxoSmithKline

Jack Bailey joined GlaxoSmithKline in 2009 to lead the Private, Public and Institutional Customers (PPIC) division for US Pharma. This division pulls together Public Policy & Patient Advocacy, Government Affairs, Payer Markets and Medical Center Sales, ensuring a holistic approach to U.S. health care policy, funding and institutional delivery. In addition Jack has responsibility for GSK’s Puerto Rican operations and recently acquired Vaccines which led to rebranding his division to Policy, Payers and Vaccines (PPV) for NA Pharma.

Prior to joining GSK, Jack enjoyed a successful eighteen-year career with Eli Lilly, most recently serving as Senior Vice President, Account-based Markets Division. Jack had a series of roles of increasing importance while with Lilly, including general manager for Eli Lilly South Africa and later Area Director for the Sub-Saharan region.

Jack received his BS in biology with a concentration in genetics from Hobart College, Geneva, New York and his MBA at the University of North Carolina at Chapel Hill. Jack and his wife, Robin reside in Raleigh, North Carolina with their two children, Emily and John.

Ben Bonifant
Practice Area Leader
Campbell Alliance

Ben Bonifant is the leader of Campbell Alliance’s Business Development practice.  In that role, Mr. Bonifant assists leaders in large and small pharmaceutical and biotechnology companies on key licensing and acquisition initiatives.  He also acts as a strategic advisor to venture capital and private equity decision makers.  Prior to joining Campbell, Mr. Bonifant was a partner in the Strategy Practice at Mercer Management Consulting.  Mr. Bonifant’s perspectives on life-sciences market developments are frequently published in industry and strategy journals, including Nature Biotechnology, Scrip, InVivo, and Pharmaceutical Executive.  Mr. Bonifant is a member of the faculty of BIO’s Business Development Basics and Advanced Business Development Professional Development Courses, and he is the co-chairman of the biannual LES Royalty Rate Survey Committee.  He is currently serving on the National Program Committee for the 2011 BIO International Convention.  Mr. Bonifant earned an MBA from the Stanford Graduate School of Business and a BS from Duke University.

Dale Christensen, Ph.D.
President & Chief Scientific Officer
Oncotide Pharmaceuticals

Dr. Christensen comes to Oncotide from Cognosci where he was VP of Research. He is also an Adjunct Associate Professor of Medicine (Hematology) at Duke University Medical Center and has 18+ years of research experience at the interface of chemistry and biology, with senior positions at Cognosci, Affinergy Inc., Aryzun Pharmaceuticals, and KaroBio USA, formerly Novalon Pharmaceuticals.  Dr. Christensen received his B.S. in Chemistry from Utah State University, and a Ph.D. in Organic Chemistry from the University of Utah.  He was an NIH Postdoctoral Fellow at Texas A&M University.  He has published many papers and is an inventor on numerous patents and patent applications in drug discovery. Dr. Christensen currently serves as a member of the MOSS(T) SBIR study section and has been the PI on numerous grants from the NIH and DOD.

Mark Clemens Ph.D
VP & Senior Scientific Officer
HepatoSys Inc.

Mark Clemens received his PhD in Physiology from St. Louis University and did postdoctoral research and served as Research Scientist at Yale Medical School. He served as Director of Research for Pediatric Surgery at Johns Hopkins School of Medicine for ten years before moving to University of North Carolina at Charlotte as Chair of Biology. In 2005 Dr. Clemens stepped down as Chair of Biology and cofounded HepatoSys Inc. based on technology developed as part of a Bioengineering Research Partnership grant from the NIH on which Dr. Clemens was principal investigator. He now serves as vice president and chief scientific officer of HepatoSys. Dr. Clemens’ research interests are in the area of regulation of liver blood flow and metabolism, shock and critical care, organ preservation and tissue engineering. His research has been continuously funded by the NIH for over 25 years.  He is an associate editor of the journal Shock, a past president of the Shock Society, a member of the Shriners Research Advisory Board and has served on numerous NIH study sections.

Deborah Dunsire, MD
President and CEO
Millennium: The Takeda Oncology Company

Deborah Dunsire MD has been the President and Chief Executive Officer of Millennium Pharmaceuticals Inc., since July 2005. In 2008 Millennium was acquired by Takeda Pharmaceuticals of Japan, becoming the global oncology center of excellence for Takeda under her leadership.  Dr. Dunsire joined Millennium from her role as Senior Vice President and North American region head of the Oncology Business Unit of Novartis in July 2005. Prior to her move to the US in 1994 – Dr. Dunsire worked in the global headquarters of Sandoz in Switzerland managing launch and growth of global products in the field of immunology and dermatology. She joined Sandoz in South Africa in 1988 as a clinical researcher and expanded her resume to include portfolio and specialty market management.

Dr. Dunsire is a member of the Board of Directors of Allergan Inc. and serves as a Director of the Biotechnology Industry Organization where she co-chairs the Committee on Reimbursement and serves as a member of the Executive Committee. Her not for profit board memberships include CancerCare Inc; the Gabrielle’s Angel Foundation for Cancer Research, the Boston Museum of Science where she chairs the Investment Review Board and she is also a member of the Massachusetts General Hospital Research Advisory Council. She served as a Director of Pharmaceutical Research and Manufacturers of America (PhRMA) from 2005-2008 and as a Director of California Healthcare Institute from 2002 - 2005. Dr. Dunsire was the 2001 recipient of the American Cancer Society Excalibur Award, the 2000 recipient of the Health Care Business Women's Association Rising Star Award, the 2009 Health Care Business Women’s Association Woman of the Year Award, 2011 Massachusetts Biotechnology Organization’s Innovative Leadership Award, and the 2011 Golden Door Award from the International Institute of New England. She received a PhD Honoris Causa from Worcester Polytechnic Institute in 2007. Dr. Dunsire graduated as a physician from the University of Witwatersrand in Johannesburg, South Africa

Kenneth E. Eheman, Jr.

Partner

Wyrick Robbins

Ken is a partner at Wyrick Robbins, one of the Southeast’s leading entrepreneurial law firms.  Ken is the leader of the firm’s Life Sciences Industry Team and practices in the area of corporate and securities law, including company formation, venture capital financings, private placements, public offerings, mergers & acquisitions and strategic partnerships.  Ken’s experience includes representing start-up and emerging growth companies, public companies, underwriters and venture capitalists.  Ken joined Wyrick Robbins in 1998 from New York where he practiced at Skadden, Arps, Slate, Meagher & Flom LLP and Brobeck, Phleger & Harrison, LLP.  Ken has a BSBA from the University of North Carolina at Chapel Hill and a JD from the University of Pennsylvania Law School.

Eric Faulkner
Director – Global Market Access, Consulting
Quintiles

Eric Faulkner heads Quintiles’ reimbursement, pricing and market access and commercialization strategy consulting. Before joining Quintiles in 2011, Eric managed a portfolio of projects at RTI Health Solutions, the Littell Group, and The Lewin Group. He was an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology. Eric is Chair of the ISPOR Personalized Medicine Special Interest Group; is Executive Director of the Genomics Biotech and Emerging Medical Technology Institute of the National Association of Managed Care Physicians; and is an adjunct Assistant Professor at UNC-Chapel Hill.

Neal Fowler
CEO
Liquidia Technologies Inc.

Mr. Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Neal served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases.  At Centocor, Mr. Fowler prepared the company for the launch of two potential blockbuster products and continued the company's legacy of double-digit growth for their flagship product REMICADE® (infliximab).  Prior to Centocor, Mr. Fowler was president of Ortho-McNeil Neurologics Inc. and vice president of the central nervous system franchise at Ortho-McNeil Pharmaceuticals.  Mr. Fowler joined J&J after a successful 13-year career at Eli Lilly and Company, where he held a variety of sales, marketing and business development roles with increasing responsibilities in both the pharmaceutical and medical device divisions.  Mr. Fowler is a native of Raleigh, NC and received a Bachelor of Science degree in Pharmacy and Masters of Business Administration from the University of North Carolina at Chapel Hill (UNC-CH).

Nicole R. Fox,
SBIR/STTR Program Coordinator
US Army Research Office

Nicole Fox serves on the staff of the Army Research Office (ARO) in Durham, NC as the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program Coordinator. She has held this position since August 2011.  In this capacity she coordinates all aspects of ARO’s participation in the SBIR/STTR Programs of the Army and other DoD agencies.  Prior to assuming her current role, Ms. Fox served from 2001 through 2005 and again from 2010 through 2011 as the Program Specialist for the Army Small Business Technology Transfer (STTR) program. During her years of service she specialized in reviewing and recommending improvements for program execution processes (topic selection, proposal evaluation, and contract award and execution). She also manages the topic development processes, coordinates all aspects of program administration with Army Program Mangers, oversees the proposal evaluation process, and conducts debriefings.

Vipin K. Garg, Ph.D.
President and CEO
Tranzyme Pharma

Dr. Garg has served as Tranzyme’s President and Chief Executive Officer and as a member of its board of directors since late 2000. Under his leadership, Tranzyme has advanced two internally-discovered drug candidates into late-stage clinical development and the company has secured more than $140 million of new capital, including net proceeds of $51.4 million as part of the Company’s initial public offering in April 2011. Prior to joining Tranzyme, Dr. Garg was COO of Apex Bioscience (now Curacyte AG of Munich, Germany), and held senior management positions at DNX Therapeutics [NASDAQ: DNXX] until its acquisition by Baxter in 1994, Sepracor, Inc. (now Sunovion) and Bio-Response Inc. (acquired by Baxter).

Dr. Garg is a past member of the board of the NC Biotechnology Center, currently serves on the Executive Committee of CED (formerly the Council for Entrepreneurial Development) and is the recipient of the Ernst & Young Entrepreneur of the Year 2009 Award, Carolinas Region. He was also a member of the US Presidential Mission to India led by President Bill Clinton in March, 2000. He holds an M.S. from Delhi University, New Delhi, India, and a Ph.D. in biochemistry from the University of Adelaide, Australia.

Amy L. Grogg
President
Xcenda

Amy L. Grogg, PharmD, is President of Xcenda.  Dr. Grogg leads the company's strategic direction to ensure that Xcenda consistently advances its leading market position. Dr. Grogg joined Xcenda in 2005 and was previously Vice President, leading the Reimbursement and Value consulting teams.  

Dr. Grogg's extensive experience includes more than 150 unique research studies and strategic marketing engagements. Her work in the pharmaceutical industry has included pharmacoeconomics, quality of life, and outcomes management research as well as presentations and publications for developmental and marketed products in hypercholesterolemia, oncology, analgesia, neurology, osteoporosis, pain management, psychiatry, neurology, gastroenterology, and many other therapeutic areas. Dr. Grogg is the Chair of Research Committee for the Foundation of Managed Care Pharmacy and she is the immediate past chair of the Institutional Council for the International Society of Pharmacoeconomics and Outcomes Research.  

Prior to joining Xcenda, Dr. Grogg held various internal and regional positions within the Outcomes Research group at Janssen Pharmaceutica. She most recently led the Outcomes Research and Medical Informatics groups responsible for all health economic, quality of life, and patient-reported outcomes research studies as well as statistical analysis support for Medical Affairs activities for all marketed products from Janssen Pharmaceutica in the US. She was a member of the Medical Affairs Management Team, Chairman of the J&J Global Health Economics and Outcomes Research Council, and Chairman of the Janssen Women’s Leadership Initiative.  

Dr. Grogg received her Doctor of Pharmacy from Mercer University, Southern School of Pharmacy and completed a clinical practice residency at Hamot Medical Center in Erie, PA. She also completed a 2-year fellowship in pharmacoeconomics at Sandoz Pharmaceuticals Corporation and the University of South Carolina.

James Geraghty
Senior Vice President North American Strategy and Business Development
Genzyme

James Geraghty is Senior Vice President North American Strategy and Business Development.  In this role he oversees strategic and business development initiatives for Genzyme and for Sanofi’s Pharmaceuticals businesses based in North America.  

He was President of Genzyme Europe from 1998-2002, and General Manager of Genzyme’s cardiovascular business from 2003-2008.  From 2008-2010 he oversaw strategic initiatives in emerging markets and led most of Genzyme’s major strategic transactions.

Mr. Geraghty also oversaw Genzyme’s Humanitarian Assistance for Neglected Diseases program.  He served as Co-Chair of the executive committee for BIO 2007 and a founder of the Partnering for Global Health Forum.  He is currently on the boards of MMV North America and Bio Ventures for Global Health.

Mr. Geraghty was earlier Chairman and CEO of GTC Biotherapeutics, which he took public in 1993.  Prior to that he led healthcare strategy teams at Bain and Company and early stage investments for Bain Capital.  A graduate of the Yale Law School, he holds a masters degree from the University of Pennsylvania and a bachelor’s degree from Georgetown University.

Caroline Green
Integration, Quality and Regulatory Manager
InnerOptic Technology, Inc.

Ms. Green has extensive experience as a published researcher and NSF grant manager at UNC's world-renowned Computer Science Department.  Since joining InnerOptic in 2004, Ms. Green has secured and managed multiple NIH SBIR grants, managed the successful FDA clearance for InnerOptic's AIM needle guidance device, managed the successful AIM clinical trial at the Carolinas Medical Center, co-authored multiple research publications, co-invented multiple patents, and led the integration of multiple technologies into InnerOptic's products.

Steven E. Hall, Ph.D.
Venture Partner
Lilly Ventures

Steve is currently a Venture Partner at Lilly Ventures, following more than 25 years of drug discovery experience at both multinational pharmaceutical companies and biotech organizations. Prior to joining Lilly Ventures in 2009, Steve was Senior Vice President, Research and Development, at Serenex, Inc. where he was also a co-founder.  There he recruited and led a team in developing a novel discovery technology and applied it to a project that advanced from a novel screen to first patient dosed in just over three years. This novel orally-active Hsp90 inhibitor was the subject of strong interest across the industry and led to the acquisition of Serenex by Pfizer in April 2008.

Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology.  There he was a key member of a small team that developed and executed a strategy to partner Lilly’s expertise in high-throughput chemistry with three Japanese pharmaceutical companies with an aggregate value of more than $75MM.  
Steve started his career in 1982 at the Squibb Institute for Medical Research as a medicinal chemist where he was involved with multiple projects in cardiovascular disease and inflammation.

Steve is an author/co-author of more than 40 papers and 60 patents.  He received his B.S. in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology.  Steve sits on the boards of Cerulean Pharma, FORMA Therapeutics, Hydra Biosciences, InnoCentive and Nimbus Discovery and is a board observer at Viamet.

William A. Hawkins
Retired Chairman and CEO
Medtronic, Inc.

Bill Hawkins assumed the role of Chief Executive Officer of Medtronic, Inc. in August 2007 and became Chairman of the Board in August 2008.  Hawkins was named President and Chief Operating Officer in May 2004 after joining Medtronic as Senior Vice President and President of Medtronic's Vascular business in January 2002.

Hawkins joined Medtronic from Novoste Corp., where he had been President and Chief Executive Officer since 1998. Earlier positions included Corporate Vice President and President of the Sherwood Davis and Geck organization of American Home Products; President of the Ethicon Endo-Surgery organization of Johnson & Johnson; President, Devices for Vascular Intervention and President U.S. Operations, for Guidant Corp.; and several increasingly responsible executive positions culminating in the presidency of the IVAC organization for Eli Lilly & Co. He began his medical technology career with Carolina Medical Electronics in 1977.

Hawkins received his Bachelor of Science degree in electrical and biomedical engineering from Duke University in 1976 where he also conducted medical research in pathology. He received a Master of Business Administration Degree from the Darden School of Business, University of Virginia, in 1982.

Hawkins is a member of the Duke University Board of Trustees, the Board of Visitors of the Engineering School of Duke University and the Minneapolis Institute of Arts.

Chris Hite
Co-Head, Healthcare Investment Banking
Citigroup

Chris is the Global Head of Health Care Investment banking at Citigroup.  He manages 145 bankers in 19 countries that provide M&A advice and help with the capital formation needs of healthcare companies globally. During 2009 and 2010, the Citi Healthcare group has helped clients raise over $101 billion in capital through the debt and equity markets and has advised on over $127 billion in mergers and acquisitions. Prior to joining Citi, Chris was the Global Head of Health Care at Lehman Brothers. Chris has worked on hundreds of transactions involving mergers and acquisitions and financings with companies across the various sub-sectors of Healthcare. Representative transactions include: HCA’s IPO ($3.8 bn), Pfizer's acquisition of Wyeth ($67 bn), HCP’s acquisition of ManorCare ($6 bn), Astellas acquisition of OSI ($4.0 bn), Elan’s US strategic collaboration and equity investment from Johnson & Johnson ($1.4 bn), MGI Pharma’s sale to Eisai ($3.9 bn), Warner Chilcott’s acquisition of P&G Pharma ($2.9bn), MedImmune’s acquisition of Aviron ($1.6 bn), Genzyme acquisitions of Bone Care ($700mm), BioChem Pharma’s sale to Shire ($4.0 bn), Serono Convertible Bond offering ($500 mm) and Celgene’s acquisition of Anthrogenesis. Chris received his B.S. from Lehigh University and his JD/MBA from the University of Pittsburgh

R.T. (Terry) Hisey
Vice Chairman and U.S. Life Sciences Leader
Deloitte LLP

R.T. (Terry) Hisey is the Vice Chairman and U.S. Life Sciences Leader for Deloitte LLP.  In this role, Terry leads the firm’s service efforts in the areas of audit, tax, strategy, performance improvement and technology consulting to assist clients in achieving sustainable competitive advantage through strategic change.  His life sciences experience spans the entire value chain including drug discovery & development, commercial operations, production & distribution, and regulatory compliance. As Chairman of the Life Sciences Advisory Board for Deloitte Research and Steering Committee member for the Deloitte Center for Health Solutions, Terry guides thought leadership and advises clients on transformative opportunities in the industry including comparative effectiveness, informatics, social media and globalization.

In addition to his client work, Terry is a noted industry authority, frequent speaker, a Strategy Advisor to Pharmaceutical Executive Magazine, and guest lecturer at several schools including the University of Pennsylvania, and the University of California at Berkeley.  Terry is also a member of several industry associations and advisory boards.

Kinney Horn
Associate Director in Business Development
Genentech

Kinney Horn is an Associate Director in Business Development at Genentech. Mr. Horn is involved in licensing transactions for novel therapeutics, technologies and intellectual property. Mr. Horn works with biotechnology companies that Genentech has invested in through its GenenFUND, Genentech’s private equity fund.

Mr. Horn joined Genentech in 2003 in the R&D finance group. From 2003 to 2005, he held positions of increasing responsibility supporting 10 molecules in Genentech’s portfolio as a Financial Analyst, the B-cell franchise core team as a Senior Financial Analyst, and Genentech’s business development transactions as a Finance Manager.

Prior to Genentech, Mr. Horn worked with life science companies as part of venture capital investments and investment banking transactions at Emerging Technology Partners and Oscar Gruss & Son respectively. Mr. Horn holds a B.A. in Economics and Int'l. Affairs from Mary Washington College and M.S. in Biochemistry from Georgetown University.

Mehmood Khan, M.D.
CSO and CEO
Global Nutrition Group
PepsiCo

Mehmood Khan, M.D., is Chief Executive Officer, Global Nutrition Group, and Chief Scientific Officer of PepsiCo, the food and beverage company with the most billion-dollar brands worldwide. Dr. Khan leads Company-wide research and development and has overseen PepsiCo’s expanded investment in R&D by recruiting highly regarded clinical scientists, global health leaders and medical experts. As CEO, Global Nutrition Group, he directs PepsiCo’s enterprise planning, portfolio development, and execution of new technology to accelerate growth of a global architecture for the Company’s nutrition-focused brands. Previously, Dr. Khan was a faculty member at the Mayo Clinic, serving as Director of the Diabetes, Endocrine and Nutritional Trials Unit in the division of endocrinology.

Kris H. Jenner, M.D., D. Phil
Vice President
T. Rowe Price Group

Kris H. Jenner is lead portfolio manager for T. Rowe Price's Health Sciences Strategy and a vice president of T. Rowe Price Group, Inc. Dr. Jenner has been managing health care portfolios for T. Rowe Price since 2000 and also acts as its lead analyst for biotechnology and U.S. pharmaceutical companies. He serves on the Investment Advisory Committees for many of the firm's strategies with health care exposure, including U.S. Large-Cap Growth, U.S. Large-Cap Core Growth, U.S. Mid-Cap Growth, and U.S. Small-Cap Stock.

Dr. Jenner has 16 years of investment experience, interspersed with a successful medical career. He joined T. Rowe Price in 1997 as a health care sector analyst after leaving the Laboratory of Biologic Cancer of The Brigham & Women's Hospital of Harvard Medical School. Dr. Jenner served his residency at the Johns Hopkins Hospital Department of General Surgery from 1993 to 1995. He also started and was portfolio manager for the Oxford Capital Group, where he managed a private hedge fund specializing in the health care sector.

Dr. Jenner graduated summa cum laude and as a member of Phi Beta Kappa from the University of Illinois with a B.S. in Chemistry. He received a D. Phil. from Oxford University as a Marshall Scholar and an M.D. from the Johns Hopkins University School of Medicine.

Mark Levin
Partner
Third Rock Ventures

Mark Levin is an industry visionary with more than 25 years of experience building and operating leading biotech companies. Mark co-founded Third Rock Ventures in 2007 and focuses on the formation, development and business strategy of our portfolio companies, as well as actively identifying and evaluating new investments.  He also assumes active leadership roles in our portfolio companies, functioning as CEO through the first 12-18 months post launch.

Mark was co-founder of Mayfield Fund's life sciences effort where he was also the founding CEO of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells and Millennium Pharmaceuticals.  Mark served as CEO of Millennium Pharmaceuticals for 12 years. Earlier in his career, Mark was a scientist at Lilly and Genentech.

Mark holds an MS in Chemical and Biomedical Engineering from Washington University. He is a member of the National Academy of Engineering, and the Friends of Personalized Medicine, and he co-founded the Possible Project in Cambridge, MA.

David Levison
President and CEO
CardioDx

David Levison is the Founder, CEO, and Director of CardioDx.  Prior to launching CardioDx, David was a Venture Partner at TPG Ventures and was the CEO of XDx. Previously, he was the founder, President and CEO of iScribe (which was sold to AdvancePCS-now Caremark in December, 2001). Prior to iScribe, David was President of Oncology Therapeutics Network (sold to Bristol-Myers Squibb in 1996). David also served as CFO of OTN's parent company, Axion, from 1990 to 1993. Prior to Axion, he was with Cole Gilburne Fund, an early stage, technology focused venture capital firm. David received his MBA from Stanford University and BS from Williams College.

Ann-Marie Lynch
Executive Vice President
The Advanced Medical Technology Association (AdvaMed)

Ann-Marie Lynch is the Executive Vice President, Payment and Health Care Delivery at the Advanced Medical Technology Association (AdvaMed).  In that role she manages the team that oversees the development of AdvaMed’s payment and coverage polices and positions on a wide range of Medicare and private health care issues.  Prior to joining AdvaMed, Ms. Lynch was the Principal Deputy Assistant Secretary for Planning and Evaluation (ASPE) at the U.S. Department of Health and Human Services and served as the Deputy Assistant Secretary, Health Policy in ASPE.  She was the Staff Director of the U.S. House of Representatives, Committee on Ways and Means, Health Subcommittee where she played a key role in the development of major health care legislation.  Ms. Lynch was a Senior Policy Analyst at the Prospective Payment Assessment Commission (now MedPAC) and an Economist at the Health Care Financing Administration (now CMS).  She holds a B.A. from Fairfield University and an M.A. from Duke University, both in Economics.

Ajay Rai

Director of Business Development & Mergers and Acquisitions

Biogen Idec

Ajay Rai is Director of Business Development & Mergers and Acquisitions at Biogen Idec and has served in this position since April 2011.  In this capacity Ajay is responsible for leading the evaluation of all acquisition and large scale partnering opportunities. Ajay joined Biogen Idec in 2005 in the Business Planning department, working with R&D management on financial and strategic planning activities.  From 2008 through 2009, Ajay was an Associate Director in the Investor Relations Department, and subsequently from 2009 through 2010 was Director of Strategic Analyses. In this role Ajay worked closely with senior management in defining corporate strategy and also led the financial analysis of M&A and partnering transactions.  Prior to Biogen Idec, Ajay worked in the M&A and Private Placements department of Ernst & Young LLC for four years, raising venture capital for early stage technology and specialty pharmaceuticals companies and advising privately held companies on strategic alternatives. Ajay holds a B.S. degree in Finance from Stern School of Business at New York University  and an M.B.A. from Case Western Reserve University.

Colin Roskey

Partner

Alston & Bird LLP

Colin Roskey is a partner in Alston & Bird's health care practice, based in Washington DC.  He advises device, diagnostic and pharmaceutical manufacturers on a variety of statutory, regulatory and public policy, focusing on coverage and payment issued under Medicare.  A former Sentate Finance Committee Part B services counsel for then-Committee Chair Chuck Grassley (R-IA), Colin worked on a small team responsible for CMS program oversight and policy development that lead to passage of the Medicare Modernization Act of 2003.

Robert J. Schotzinger, M.D., Ph.D.
President and CEO
Viamet Pharmaceuticals

Robert J. Schotzinger, M.D., Ph.D., is President and CEO of Viamet Pharmaceuticals, Inc.  He brings nearly 20 years of research, development and management experience to Viamet, where he has raised $32 million in private equity, completed three major corporate partnerships and moved Viamet from a discovery-stage company to a clinical-stage company.  Prior to joining the Company, Dr. Schotzinger was President and CEO of BioStratum Inc., a privately-held biotechnology company, where he was responsible for moving the company's lead drug candidate from phase I to phase 3.  Dr. Schotzinger began his pharmaceutical career at Abbott Laboratories where he held positions of increasing responsibility, including Director of International Medical Affairs and Vice President of Drug Development.  While at Abbott, he gained experience in preclinical and clinical drug development and was involved in the filing and approval of multiple NDAs, SNDAs, ANDAs and INDs.

Dr. Schotzinger received his B.S. in Pharmacy from the Ohio State University.  He subsequently earned his Ph.D. (Pharmacology) and medical degree from Case Western Reserve University.  He also completed a residency in Internal Medicine at the University of Virginia, which led to Board Certification in Internal Medicine.

Daniel Shaughnessy, Ph.D
Susceptibility and Population Health Branch, Division of Extramural Research and Training
National Institute of Environmental Health Sciences

Daniel Shaughnessy is currently a Program Administrator in the Susceptibility and Population Health Branch in the Division of Extramural Research and Training at the National Institute of Environmental Health Sciences (NIEHS) in RTP, North Carolina. He manages a portfolio of grants related to DNA Repair and Mutagenesis, and on biomarker development and was the Program Administrator on initiatives within the NIH Genes, Environment and Health Initiative - Exposure Biology Program, to develop improved measures of biological response to environmental stressors.  He is the NIEHS contact for SBIR/STTR programs.  He did his postdoctoral work with Jack Taylor in the Laboratory of Molecular Carcinogenesis at NIEHS, carrying out research on the risk and protective effects of dietary factors on DNA damage in humans. He received his PhD from the University of North Carolina at Chapel Hill in 2002, working with David DeMarini at the USEPA on studies of the mechanisms of antimutagenesis in multiple model systems. He received an MSPH degree from UNC-CH in 2000.

Mark A. Sirgo, Pharm.D.
President and Chief Executive Officer
BioDelivery Sciences International (BDSI)

Mark A. Sirgo, Pharm.D., has been President and Chief Executive Officer of BioDelivery Sciences International (BDSI) since July 2005. He joined BDSI in August 2004 as Senior Vice President of Commercialization and Corporate Development upon the acquisition of Arius Pharmaceuticals, of which he was a co-founder and Chief Executive Officer. He has also served as Executive Vice President, Corporate and Commercial Development and Chief Operating Officer of BDSI. Dr. Sirgo has nearly 30 years of experience in the pharmaceutical industry, including 16 years in clinical drug development, 7 years in marketing, sales, and business development and 8 years in executive management positions. Prior to his involvement with Arius Pharmaceuticals from 2003 to 2004, he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome, among other accomplishments. From 1996 to 1999, Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc. (NASDAQ:PPDI), a leading contract service provider to the pharmaceutical industry. Dr. Sirgo serves on the Board of Directors of Salix Pharmaceuticals, Inc. (NASDAQ:SLXP), a specialty pharmaceutical company specializing in gastrointestinal products since 2008. Dr. Sirgo received his BS in Pharmacy from The Ohio State University and his Doctorate from Philadelphia College of Pharmacy and Science.

Bill Slattery
Partner
Deerfield Management Company

Bill began the first 7 years of his career in basic research and healthcare delivery. In 1990 he joined Amerindo Investment Advisors as Senior Biotech Analyst.  In February of 2000 Bill joined Deerfield Management with a focus in life sciences. Bill has degrees in Biochemistry from State of University of New York at Albany and the Graduate School, Rutgers University.

John Ujvari
SBIR Program Specialist
NCSBTDC

John Ujvari is the SBIR Program Specialist with the North Carolina Small Business and Technology Development Center (SBTDC). His primary responsibilities include counseling clients on the effective use of this federal funding program and supporting and promoting SBIR educational opportunities throughout the state via numerous outreach efforts. These efforts include the publication of a monthly SBIR-focused newsletter, planning and execution of training events statewide including two national –level events, meeting clients one-on-one and reviewing proposals prior to submission. He also leads the SBTDC's MBA summer internship program. Since joining the SBTDC in 2001, SBIR and STTR awards in North Carolina have increased 5-fold. During his tenure at the SBTDC, he was awarded the State Star Award by the Association of Small Business Development Centers and the Tibbetts Award by the Small Business Technology Council.

John earned his MBA degree from Wake Forest University's Babcock Graduate School of Management with concentrations in business development, marketing and IT management. During the MBA program he was a consultant with two start-up firms where he led the business development process, managed technical resources and directed product development and rollout efforts.

Prior to returning to graduate school, John held the position of Research Associate at Westat, a contract research firm in Rockville, Maryland. He was integrally involved in a number of large-scale NIH and NCI contract studies, primarily as a technical liaison between clients and database developers. John earned his undergraduate degree from the University of Virginia.

Tim Willis
President and CEO
TearScience

Tim Willis is President, CEO & Co-Founder of TearScience.  Tim has over 35 years of medical device industry experience. Tim is an entrepreneur and inventor with numerous patents and has been responsible for the development and launch of 50+ products that today represent over half billion in annual sales.  He has co-founded or helped establish 5 medical device companies and one consulting business. He has served roles in senior management, R&D, marketing, and corporate and business development at several leading healthcare corporations. Tim is a scientist and engineer who sit on the Board of Directors of TearScience, Life Branch Institute and Trinity Academy. He is a Member of the American Society of Cataract and Refractive Surgery, Association of Research in Vision and Optics, Licensing Executive Society and a Fellow of the American Academy of Optometry.

Scheduling is on a first-registered, first-scheduled basis!

What Can You Expect From Partnering 2012?

• Unique opportunities to meet privately with leading and emerging life science companies
• The chance to meet tech transfer officers from the state's top academic centers and discuss their universities' most promising life science technologies
• Access to the CED Life Science Conference, with an excellent speaker line-up including: Chris Viehbacher (CEO, Sanofi-Aventis), Alex Gorsky (Vice Chairman, J&J's Executive Committee) and Bill Hawkins (Retired CEO, Medtronic)

Why Register for Partnering 2012?

You'll gain access to companies like these (Partnering 2011 participants):

* AstraZeneca * Biogen Idec * GSK * Lilly*

* Merck * Novo Nordisk * Pfizer *

* 40+ NC-Based Biotech Companies *

* Top University Tech Transfer Offices *

What Can I Do with the Partnering 2012 Software Tool?

The tool will allow you to:

• Customize your personal and company profile
• Search individual and company profiles
• Review the full conference agenda
• Get to know and network with conference attendees prior to the conference
• Follow up with other conference attendees during and after the conference
• Post videos, documents, and photos
• Create open/closed or private groups within the Partnering 2012 community
• And so much more!

How Do I Receive My Partnering 2012 Credentials?

Once you register for the conference and Partnering 2012, you will receive Partnering 2012 login credentials and instructions on what to do next from pamela_fincher@ncbiotech.org within one week.

What Is The Cost of Partnering 2012?

In addition to the conference registration fee:

• For Life Science Companies -- FREE
• University Technology Transfer Representatives -- FREE
• Life Science Institutional Investors -- FREE
• North Carolina-based Service Providers -- $250
• Service Providers from outside North Carolina -- $500

To view sponsorship information in a PDF version, click here.

If you're interested in sponsoring, contact Miriam Wilson (mwilson@cednc.org or 919.226.0474)

Headline Sponsor - $25,000    

•    Industry exclusive
•    Limited availability
•    Two opportunities to speak at podium during conference
•    Invitation for one to CEO Breakfast
•    Invitation for one to CED/NCBC/NCBIO Board Lunch
•    Invitation for one to Entrepreneur Workshop
•    Invitation for one to Grant Workshop
•    Premier exhibit space
•    Special signage at the conference
•    Full page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Five (5) complimentary conference registrations; additional company representative registrations
     at preferred rate of $275 (registrations are non-transferable)

Gala Reception Sponsor - $15,000  

•    Industry exclusive
•    Limited availability
•    Opportunity to speak at podium to welcome attendees to the Gala Reception
•    Invitation for one to CED/NCBC/NCBIO Board Lunch
•    Premier exhibit space
•    Prominent signage at the Gala Reception
•    Full page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Four (4) complimentary conference registrations; additional company representative registrations
     at preferred rate of $275 (registrations are non-transferable)

Annual “State of the Industry” Report Sponsor - $15,000 *SOLD*

•    Industry exclusive
•    Limited availability
•    Opportunity to present report
•    Invitation for one to CED/NCBC/NCBIO Board Lunch
•    Premier exhibit space
•    Special signage
•    Full page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Four (4) complimentary conference registrations; additional company representative registrations
     at preferred rate of $275 (registrations are non-transferable)

Lunch Sponsor — $15,000

•    Industry exclusive
•    Limited availability
•    Opportunity to speak at podium during lunch
•    Invitation for one to CED/NCBC/NCBIO Board Lunch
•    Premier exhibit space
•    Logo on table tents on each table at lunch
•    Full page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Four (4) complimentary conference registrations; additional company representative registrations
     at preferred rate of $275 (registrations are non-transferable)

Featured Speaker Sponsor — $10,000

•    Industry exclusive
•    Limited availability
•    Opportunity to speak at podium
•    Exhibit space
•    Special signage
•    Half page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Three (3) complimentary conference registrations; additional company representative registrations
      at preferred rate of $275 (registrations are non-transferable)

CED, NC Biotechnology Center and NCBIO Board Lunch Sponsor - $10,000

•    Industry exclusive
•    Limited availability
•    Opportunity to speak at podium during lunch with board members of the three host organizations
•    Two (2) complimentary board lunch registrations (registrations are non-transferable)
•    Exhibit space
•    Logo on table tents on each table at lunch
•    Half page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Three (3) complimentary conference registrations; additional company representative registrations
     at preferred rate of $275 (registrations are non-transferable)

Lanyard Sponsor - $10,000

•    Limited to one sponsor
•    Company logo branded on attendee name badge lanyards given to each attendee
•    Exhibit space
•    Half page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Three (3) complimentary conference registrations; additional company representative registrations
     at preferred rate of $275 (registrations are non-transferable)

Back Cover Sponsor - $10,000

•    Limited to one sponsor
•    Full page color ad on back cover of conference book
•    Exhibit space
•    Half page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Three (3) complimentary conference registrations; additional company representative registrations
     at preferred rate of $275 (registrations are non-transferable)

CEO Breakfast Sponsor - $7,500  

•    Industry exclusive
•    Two (2) complimentary registrations to CEO breakfast (registrations are non-transferable)
•    Exhibit space
•    Special signage at Breakfast
•    Half page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Two (2) complimentary conference registrations; additional company representative registrations
      at preferred rate of $275 (registrations are non-transferable)

Partnering Sessions Sponsor - $7,500

•    Industry exclusive
•    Recognition as a sponsor on all Partnering Program information
•    Exhibit space
•    Special signage
•    Half page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Two (2) complimentary conference registrations; additional company representative registrations
      at preferred rate of $275 (registrations are non-transferable)

Presenting Companies Sponsor - $7,500

•    Limited to two (2) sponsors
•    Opportunity to introduce presenting companies at the podium
•    Exhibit space
•    Special signage
•    Half page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Two (2) complimentary conference registrations; additional company representative registrations
     at preferred rate of $275 (registrations are non-transferable)

Wireless Sponsor - $7,500

•     Limited to one (1) sponsor
•     Company name used as wireless password
•     Exhibit space
•     Special signage
•     Half page advertisement in conference book
•     Logo on all conference marketing materials
•     Logo hyperlink to your website
•     Two (2) complimentary conference registrations; additional company representative registrations
       at preferred rate of $275 (registrations are non-transferable)

Entrepreneur Workshop Sponsor - $6,000  

•    Industry exclusive
•    Two (2) complimentary Entrepreneur Workshop registrations (registrations are non-transferable)
•    Podium time during Entrepreneur Workshop
•    Exhibit space
•    Quarter page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Two (2) complimentary conference registrations; additional company representative registrations
      at preferred rate of $275 (registrations are non-transferable)

Specialty Drink Sponsor - $6,000  

•    Industry exclusive/limited availability
•    Opportunity to name specialty drink
•    Special signage
•    Exhibit space
•    Quarter page advertisement in conference book
•    Logo on all conference marketing material
•    Logo hyperlink to your website
•    Two (2) complimentary conference registrations; additional company representative registrations
      at preferred rate of $275 (registrations are non-transferable)

Breakfast Sponsor - $6,000  

•    Industry exclusive/limited availability
•    Special signage during breakfast
•    Exhibit space
•    Quarter page advertisement in conference book
•    Logo on all conference marketing material
•    Logo hyperlink to your website
•    Two (2) complimentary conference registrations; additional company representative registrations
      at preferred rate of $275 (registrations are non-transferable)

Grant Workshop Sponsor - $6,000  

•    Industry exclusive
•    Two (2) complimentary Grant Workshop registrations (registrations are non-transferable)
•    Podium time during Grant Workshop
•    Exhibit space
•    Special signage
•    Quarter page advertisement in conference book
•    Logo on all conference marketing materials
•    Logo hyperlink to your website
•    Two (2) complimentary conference registrations; additional company representative registrations
      at preferred rate of $275 (registrations are non-transferable)

Break Sponsor - $6,000  

•    Industry exclusive/limited availability
•    Special signage during breaks
•    Exhibit space
•    Quarter page advertisement in conference book
•    Logo on all conference marketing material
•    Logo hyperlink to your website
•    Two (2) complimentary conference registrations; additional company representative registrations
      at preferred rate of $275 (registrations are non-transferable)

Gold Sponsor - $5,000

•    Exhibit space
•    Quarter page advertisement in conference book
•    Company name listed on all conference marketing materials
•    Hyperlink to your website
•    Two (2) complimentary conference registrations; additional company representative registrations
      at preferred rate of $275 (registrations are non-transferable)

Silver Sponsor — $3,000  

•    Opportunity to place one piece of marketing collateral on general sponsor table
•    Quarter page advertisement in conference book
•    Company name listed on all conference marketing materials
•    Hyperlink to your website
•    One (1) complimentary conference registrations; additional company representative registrations
     at preferred rate of $275 (registrations are non-transferable)

Raleigh Convention Center

CED is pleased to be bringing its Annual Biotech/Life Science Conference to the new Raleigh Convention Center. The Convention Center is the centerpiece of an energetic and sophisticated city with unparalleled charm. Just steps from the convention center, a revitalized Fayetteville Street is alive with new hotels, top-notch restaurants and eclectic shops.

Convention Center Address

500 South Salisbury Street

Raleigh, NC 27601

Phone: (919)831-6011

Parking

Parking is available in the Performing Arts Deck, located on the corner of Lenoir and Salisbury Streets. There is a fee of $7 per car. Additional parking is available one block up Lenoir Street in the underground lot located below the Marriott.

Area Hotels

Raleigh Marriott City Center

500 Fayetteville Street

Raleigh, NC 27601

Phone: (919) 833-1120

Rate is $159 plus tax with a special rate negotiated for internet at $5 per night, plus tax.
There is a limited number of rooms blocked for the CED conference.  Rooms are available first come/first serve.  After the block has been filled, rooms will be available at prevailing hotel rates.  

By Phone:
1. Call Marriott reservations at 1-800-228-9290 or 1-888-236-2427.
2. Ask for the CED Room Block (Code:CEL) for Feb 14-16, 2012.
 
Online:
1. Go to www.marriott.com/rdumc
2. Enter the dates of your stay (block dates are Feb 14-16, 2012.
3. Enter Group Code: CELCELA (not case sensitive) under the ‘Special Rates & Awards’ box
5. Click ‘Check Rates & Availability’
6. CED Room Block @ $159.00 will come up, click on Reserve a Room
7. Enter personal information and confirm reservation
 
Hotel website

Sheraton Raleigh Hotel

421 South Salisbury Street

Raleigh, North Carolina 27601

Phone: (919) 834-9900

http://www.starwoodhotels.com/sheraton/

• 0.07 miles from Convention Center
• 17.45 miles from RDU Airport

Clarion Hotel

320 Hillsborough Street

Raleigh, NC 27603-1786

Phone: (919) 832-0501

http://www.raleighclarion.com/

•  0.63 miles from Convention Center
• 12.85 miles from RDU Airport

Holiday Inn Brownstone Hotel

1707 Hillsborough Street

Raleigh, NC 27605

Phone: (919) 828-0811

http://www.brownstonehotel.com/

• 1.71 miles from Convention Center
• 11.87 miles from RDU Airport

Hampton Inn Raleigh Midtown

1001 Wake Towne Drive,

Raleigh, NC 27609

Phone: 919-828-1813

Group Code:  CED

www.raleighnorth.hamptoninn.com

• 5 miles away from the Raleigh Convention Center
• Deluxe Continental breakfast and Wi-Fi included in rate

Area Transportation

White Horse Transportation: (919) 782-5893

Action Limousine Service: (919) 796-0529

Capital Style Luxury Transportation, Inc: (919) 460-1230

Elite Coach: (919) 674-6046 x 236

Area Information

Map of Raleigh Attractions

For comments or questions regarding the information above, please contact Vance Faulkner at 919.226.0482.